EFFECT OF DIETARY/ORAL DRUGS ON THE TRACE ELEMENTS IN BREAST CANCER TISSUE

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 本研究的目的是研究饮食/口服药物替代标准化疗(滴注或输注)患者乳腺癌组织切片中微量元素的变化及其相关性。为了对乳房组织进行测量，样品被安装在专门设计的HDPE环上，外径12 mm，内径6 mm，使用kapton胶带。这种设计允许X射线束穿过样品，以记录样品后面的强度和荧光。我们对以下样本进行了评估。1.正常乳腺组织(对照标本)。 2.肿瘤来源的乳腺组织。 3.肿瘤患者接受吉西他滨化疗后的乳腺组织(自吉西他滨给药之日起5天后采集的组织)，这主要是因为5天后才开始出现变化的迹象。 4.吉西他滨给药15天后，肿瘤组织中的乳腺组织。 5.连续22天饮食/口服给药所致乳腺肿瘤组织。 6.饮食/口服药物40天后肿瘤形成的乳房组织。 我们正在评估结果，我们预计在2011年完成一组测量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The goal of this investigation is to study the changes and their correlation in the trace elements in the histological sections of breast cancer tissues from patients who are on dietary/oral drugs instead of standard chemotherapy (administered by drip or infusion). For the measurement on breast tissues the samples were mounted on specially designed HDPE rings, with an outer diameter of 12 mm and an inner diameter of 6 mm, using kapton tape. This design allowed the x-ray beam to pass through the sample for recording intensity behind the sample as well as fluorescence. We have evaluated the following samples. 1. Breast tissue from normal patient (control sample). 2. Breast tissue from tumor . 3. Breast tissue from tumor cancer patient after administering gemcitabine chemotherapy (tissue collected after 5 days starting from the day gemcitabine was administered), this is mainly because the first signs of change shows after 5 days. 4. Breast tissue from tumor after 15 days of administering gemcitabine. 5. Breast tissue from tumor from administered dietary/oral drug for 22 days. 6. Breast tissue from tumor after 40 days of dietary/oral drug. We are evaluating the results and we expect to complete the set of measurements in 2011 beamtime.